EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

BGI Genomics Co Ltd (300676) fair value: what the stock is really worth

As of Sep 22, 2026: fair value of BGI Genomics Co Ltd ¥20.06, price ¥43.81, upside -54.2%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · CN · ISIN CNE100003449

BG Thin data Sep 24, 2026

BGI Genomics Co Ltd

300676 · SHE

Weakest SetupStrongly overvalued and low quality.

!Fair value ¥20.06 · Strongly overvalued (−54%)
!Quality 44/100
!Weak Growth (revenue 5y −15.1 %/yr)
!Loss-making · -14.9% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (4/11)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain
!Weak on dividend: 2 out of 100
Watch BGI Genomics Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥130.49 ¥32.88 Fair Value ¥20.06 Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range ¥32.88 – ¥130.49 · fair‑value band ¥17.15 – ¥22.97 · the ¥43.81 price screens above the ¥20.06 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow BGI Genomics Co in your weekly email

Every Wednesday you see whether BGI Genomics Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally.

Show more

BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exome sequencing; epigenetics whole genome bisulfite sequencing and ChIp-Seq; and metagenomics and 16S/18S/ITS sequencing. It also provides RNA sequencing, long non-coding RNA sequencing, small RNA sequencing, iso-seq / pacbio transcriptome sequencing; single cell sequencing and high throughput single cell RNA-Seq; spatial transcriptome-stereo-seq; immune repertoire and pre-made library sequencing; and bioinformatics solutions. In addition, the company offers mass spectrometry, including proteomics, metabolomics, and multi-omics. Further, it provides clinical solutions for reproductive health, oncology, infectious disease, and chronic disease. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. The company was founded in 1999 and is headquartered in Shenzhen, China. BGI Genomics Co., Ltd. operates as a subsidiary of BGI Group.

Stock analysis

BGI Genomics Co Ltd (300676) currently trades at ¥43.81, while our model-based Fair Value estimate is ¥20.06, implying the stock looks roughly 118.4% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 93/100, which puts the evidence level at low.

Scenario range: ¥17.15 (bear) to ¥22.97 (bull), the price of ¥43.81 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

BGI Genomics Co Ltd reported revenue of 3.7B CNY in FY2025 versus 6.8B CNY in FY2021, a compound −14.0%/yr. Reported net income was −617M CNY in FY2025.

Key figures

Market cap 18.3B CNY (≈ $2.7B) · P/S ratio 3.69 · EPS (TTM) ¥−1.38 · Dividend yield 0.1% · Net margin −16.6% · Return on equity −6.7% · Return on assets (EBIT) 2.6% · Operating margin −2.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 26% below its 52-week high and 33% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −54%, 300676 screens richer than that median.

Fair Value models

Bear ¥17.15 Fair Value ¥20.06 Bull ¥22.97
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EV/EBITDA ¥15.53 ¥18.44 ¥21.35 67
NCAV (Graham) ¥10.15 ¥13.60 ¥20.31 54
All 2 models by family
Multiples
EV/EBITDA ¥15.53 ¥18.44 ¥21.35 67
Asset-Based
NCAV (Graham) ¥10.15 ¥13.60 ¥20.31 54

Open the full fair value analysis →

Notify me when 300676 reaches fair value

Put 300676 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 44/100

Of which business quality 45 · Market factors (momentum, volatility) 45

Profitability 7
Margins and returns on capital today
Quality Growth 33
Are margins and returns improving?
Cashflow 3
Earnings quality: real cash, not paper profit
Fin. Strength 98
Balance sheet, leverage, solvency risk
Investment 78
Disciplined investing over empire-building
Low Volatility 64
Calm price path (market factor)
Momentum 44
Price trend over the last 3–12 months (market factor)
52W Momentum 27
Distance to the 52-week high (market factor)
Net Issuance 71
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−4.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.1%
Start year 2020 (pandemic). Over 10 years: +10.9% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
29.7% (2020) → −4.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

300676 screens 118% overvalued. Compare with Thermo Fisher Scientific Inc →

Compare BGI Genomics Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 141 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 45 · Below median
Fair Value upside −54% · Below median
Profitability
Return on assets −3% · Below median
Net margin (TTM) −15% · Bottom 25%
Operating margin (TTM) −3% · Below median
Growth and dividend
Revenue growth 20% · Top 25%
Dividend yield (TTM) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.05× · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.32× · Cheapest 25%
P/S (TTM) 0.71× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 9
HEALTH (low debt)97 · sector 95
DIVIDEND (yield)2 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $658.52 $682.58 +4%
Danaher Corporation DHR $221.09 $207.76 −6%
WuXi AppTec Co 2359 HK$207.60 HK$228.36 +10%
Lonza Group LONN CHF 562.80 CHF 151.69 −73%
IDEXX Laboratories, Inc IDXX $521.50 $495.84 −5%
Agilent Technologies, Inc A $167.26 $63.90 −62%
Waters Corporation WAT $425.74 $106.31 −75%
IQVIA Holdings IQV $270.09 $295.80 +10%
Illumina, Inc ILMN $247.46 $272.21 +10%
Mettler-Toledo International Inc MTD $1,491 $635.75 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BGI Genomics Co Ltd · Fair Value
¥20.06 −118%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "BGI Genomics Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300676

Frequently asked questions

Is BGI Genomics Co Ltd (300676) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥20.06 versus a price of ¥43.81, about −54% upside (overvalued).
What is the fair value of 300676?
Our model-based fair value for BGI Genomics Co Ltd is ¥20.06 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥43.81.
What is the quality score of 300676?
BGI Genomics Co Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BGI Genomics Co Ltd (300676)?
Our model-based price target is the fair value of ¥20.06 (as of Sep 24, 2026) from 2 valuation models. Cautious scenario ¥17.15, optimistic scenario ¥22.97. It is a calculation from audited fundamentals, not an analyst target.
What is the BGI Genomics Co Ltd stock forecast for 2026?
Our models put fair value at ¥20.06, about −54% upside versus a price of ¥43.81 (overvalued). Cautious scenario ¥17.15, optimistic scenario ¥22.97. The calculation is refreshed regularly with new filings.
What is the revenue of BGI Genomics Co Ltd (300676)?
BGI Genomics Co Ltd reported trailing-twelve-month revenue of about 3.8B CNY (latest available figure, as of Sep 24, 2026).
Does BGI Genomics Co Ltd pay a dividend?
BGI Genomics Co Ltd currently shows a dividend yield of about 0.12% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of BGI Genomics Co Ltd (300676)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BGI Genomics Co Ltd it is ¥20.06 per share (as of Sep 24, 2026), against a price of ¥43.81. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is BGI Genomics Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 300676 trades above its calculated fair value: price ¥43.81, fair value ¥20.06, a gap of about −54% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300676?
No. The price is what the market pays today (¥43.81); the fair value is what the company's own numbers justify (¥20.06). For BGI Genomics Co Ltd the two are ¥23.75 per share apart. That gap is exactly why we show both numbers side by side.
How much is BGI Genomics Co Ltd worth?
The market values BGI Genomics Co Ltd at about 18.3B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥43.81; our models calculate a fair value of ¥20.06 per share.
What do the bullish and bearish scenarios say about 300676?
Our models span a range for BGI Genomics Co Ltd: cautious scenario ¥17.15, base ¥20.06, optimistic ¥22.97 per share (as of Sep 24, 2026, price ¥43.81). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BGI Genomics Co Ltd (300676)?
Balance-sheet figures for BGI Genomics Co Ltd (as of Sep 24, 2026): return on equity −6.7%, debt of 0.05 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 300676 from its 52-week high?
BGI Genomics Co Ltd trades at ¥43.81, about 26% below its 52-week high of ¥59.25 and 33% above the low of ¥32.88 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥20.06 is for.
Which stocks are comparable to BGI Genomics Co Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BGI Genomics Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price ¥43.81, calculated fair value ¥20.06 (−54%), Quality Score 44/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300676 calculated?
We run BGI Genomics Co Ltd through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥20.06, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. BGI Genomics Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BGI Genomics Co Ltd (300676)?
The closing price on Sep 22, 2026 was ¥43.81. Our model-based fair value is ¥20.06, about −54% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BGI Genomics Co Ltd right now?
The price sits above even our optimistic bull case (¥22.97). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Where does the earnings growth of BGI Genomics Co Ltd (300676) come from?
Earnings per share at BGI Genomics Co Ltd grew +6.7 % a year from 2013 to 2024. Broken into its drivers: revenue per share +12.3 %, EBIT margin −4.8 %, tax rate −0.1 %, residual (interest, one-offs) −0.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of BGI Genomics Co Ltd

How large is the market capitalisation of BGI Genomics Co Ltd (300676)?
The market capitalisation of BGI Genomics Co Ltd is 18.3B CNY (≈ $2.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BGI Genomics Co Ltd (300676)?
The price-to-sales ratio of BGI Genomics Co Ltd is 3.69 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BGI Genomics Co Ltd (300676)?
Earnings per share at BGI Genomics Co Ltd are ¥−1.38. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of BGI Genomics Co Ltd (300676)?
The dividend yield of BGI Genomics Co Ltd is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of BGI Genomics Co Ltd (300676)?
The net margin of BGI Genomics Co Ltd is −16.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BGI Genomics Co Ltd (300676)?
The return on equity (ROE) of BGI Genomics Co Ltd is −6.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BGI Genomics Co Ltd (300676)?
On an EBIT basis the return on assets of BGI Genomics Co Ltd is 2.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BGI Genomics Co Ltd (300676)?
The operating margin of BGI Genomics Co Ltd is −2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BGI Genomics Co Ltd (300676)?
Revenue at BGI Genomics Co Ltd is growing +20.4% versus a year earlier (3y avg −19.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BGI Genomics Co Ltd (300676)?
Earnings per share at BGI Genomics Co Ltd are growing +938% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does BGI Genomics Co Ltd (300676) generate?
The free cash flow of BGI Genomics Co Ltd is −569M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does BGI Genomics Co Ltd (300676) hold?
BGI Genomics Co Ltd holds more cash than debt, 3.5B CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch BGI Genomics Co Ltd in the live analysis

One click puts BGI Genomics Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.